Navigation Links
Widespread Acceptance and Use of Accuray's Technologies Continue to Grow

SUNNYVALE, Calif., Nov. 25, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today continued momentum in global adoption of its CyberKnife® and TomoTherapy® Systems. Accuray has expanded its installed base to more than 700 systems worldwide which have been used to treat more than half a million patients, further positioning the company as a leader in precise, innovative radiation oncology. To date, the CyberKnife and TomoTherapy Systems have been used in 40 countries to treat patients across the full spectrum of radiation oncology cases including prostate, lung, liver, breast and head and neck cancers.

"The CyberKnife and TomoTherapy Systems are widely recognized by the global oncology community as leading edge, innovative treatment solutions," said Joshua H. Levine, president and chief executive officer of Accuray. "These installation and patient milestones reflect our Systems' continued and growing adoption across the world. Though we are proud of these achievements, there are many more patients that could benefit from the personalized, non-invasive treatment options our technologies provide. We will continue our commitment to maximizing patient access and coverage, while working toward a future where the fear, pain and suffering of cancer are a thing of the past."

"With the ability to image my patients every day I can create highly conformal treatment plans that are more specific to the tumor and can be delivered in fewer doses, thus allowing me to treat indications ranging from breast, liver, pancreatic and head and neck cancers," said Martin Keisch, M.D., president and medical director at Cancer Healthcare Associates in Miami, Florida. "We went live with our TomoTherapy System in December 2012. We have treated more than 200 patients and our system has not been down for more than one hour. The TomoTherapy System has redefined how I deliver radiation treatment."

Accuray's newest innovations are the CyberKnife® M6™ Series and the TomoTherapy® H™ Series Systems treatment solutions. Between them the entire spectrum of radiation therapy needs are covered. The CyberKnife M6 Series offers the ability to deliver high-quality, high-dose distributions that can be confidently delivered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. The TomoTherapy H Series facilitates interactive treatment planning for clinicians to make development of customized plans for a wide range of patients and disease types efficient. The innovative design of the System allows treatment plans to be delivered with integrated, daily CT image guidance, enhancing accuracy and delivering highly precise, intensity-modulated radiation for optimal sparing of healthy tissue and critical structures.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments. For more information, please visit

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to adoption of new technologies, number of patients treated, clinical experience, clinical applications, clinical results, and the Company's leadership position in radiation oncology innovation. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the company's report on Form 10-K filed on August 29, 2013, and as updated periodically by our other filings. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.

SOURCE Accuray Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Life Technologies Announces Next-Gen Digital PCR Instrument Designed for Widespread Adoption
2. Leader In At-Home Laboratory Testing Praises Federal Panels Recommendations For Widespread HIV Testing
3. Frost & Sullivan: Digitisation of Australias healthcare system met with widespread apprehension
4. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
5. Advances in Cosmesis Increase Amputee Acceptance of Prosthesis and Orthotics Devices, Finds Frost & Sullivan
6. United Therapeutics Announces FDA Acceptance of Resubmission of Oral Treprostinil NDA
7. China Botanic Pharmaceutical Inc. Announces Acceptance of its Plan of Compliance by NYSE MKT LLC
8. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
9. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
10. Royalty Pharma Acceptances Announcement
11. Nektar Reports that Partner AstraZeneca Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):